Intravenous injection of imidazoquinoline, another TLR agonist, which site-specifically and quantitatively coupled to the nanobodies of the macrophage mannose receptor (MMR) on TAMs, led to a prominent decrease in tumor growth, along with repolarization of TAMs to a pro-inflammatory type and enhancement of anti-tumor T cell responses (86). Here, MRC1 is linked to neoplasm.